Intraoperative versus extended antimicrobial prophylaxis after gastric cancer surgery: a phase 3, open-label, randomised controlled, non-inferiority trial

Hiroshi Imamura, Yukinori Kurokawa*, Toshimasa Tsujinaka, Kentaro Inoue, Yutaka Kimura, Shohei Iijima, Toshio Shimokawa, Hiroshi Furukawa*

Summary

Background **Although evidence for the efficacy of postoperative antimicrobial prophylaxis is scarce, many patients routinely receive such treatment after major surgeries. We aimed to compare the incidence of surgical-site infections with intraoperative antimicrobial prophylaxis alone versus intraoperative plus postoperative administration.**

Methods **We did a prospective, open-label, phase 3, randomised study at seven hospitals in Japan. Patients with gastric cancer that was potentially curable with a distal gastrectomy were randomly assigned (1:1) to receive either intraoperative antimicrobial prophylaxis alone (cefazolin 1 g before the surgical incision and every 3 h as intraoperative supplements) or extended antimicrobial prophylaxis (intraoperative administration plus cefazolin 1 g once after closure and twice daily for 2 postoperative days). Randomisation was stratified using Pocock and Simon's minimisation method for institution and American Society of Anesthesiologists scores, and Mersenne twister was used for random number generation. The primary endpoint was the incidence of surgical-site infections. We assessed non-inferiority of intraoperative therapy with a margin of 5%. Analysis was by intention-to-treat. During hospital stay, infection-control personnel assessed patients for infection, and the principal surgeons were required to check for surgical-site infections at outpatient clinics until 30 days after surgery. This study is registered with UMIN-CTR, UMIN000000631.**

Findings **Between June 2, 2005, and Dec 6, 2007, 355 patients were randomly assigned to receive either intraoperative antimicrobial prophylaxis alone (n=176) or extended antimicrobial prophylaxis (n=179). Eight patients (5%, 95% CI 2–9%) had surgical-site infections in the intraoperative group compared with 16 (9%, 5–14) in the extended group. The relative risk of surgical-site infections with intraoperative antimicrobial prophylaxis was 0·51 (0·22–1·16), which revealed statistically significant non-inferiority (p<0·0001).**

Interpretation **Elimination of postoperative antimicrobial prophylaxis did not increase the incidence of surgical-site infections after a gastrectomy. Therefore, this treatment is not recommended after gastric cancer surgery.**

Funding **Osaka Gastrointestinal Cancer Chemotherapy Study Group.**

Introduction

The Centers for Disease Control and Prevention in the USA has issued guidelines that recommend administration of a first-generation cephalosporin for intraoperative antimicrobial prophylaxis to prevent surgical site infections in clean or clean-contaminated operations.[1] This treatment is usually given within 30 min of the first surgical incision, with supplementary treatments every 3 h or 4 h throughout the operation.[2] Results of a large-scale national cohort study in the USA showed that only 14·5% of 32 603 patients who had major surgery had discontinued antimicrobial prophylaxis within 12 h after the surgery ended and that 26·7% of patients were still receiving this treatment at 48 h after surgery.[3] Furthermore, a questionnaire administered to 3823 Japanese surgeons showed that 56·4% of them gave antimicrobial prophylaxis in clean-contaminated operations until 3–4 days after surgery, whereas only 2·4% of surgeons gave the treatment for 24 h or less after surgery ended.[4] Because of a high prevalence of drain use in gastrointestinal surgery in Japan and the potential risk of surgical-site infections, the Japanese Association for Infectious Diseases and the Japanese Society of Chemotherapy developed guidelines that recommend postoperative antimicrobial prophylaxis for 1–3 days after gastrointestinal surgery.[5] However, postoperative antimicrobial prophylaxis is controversial because evidence for its efficacy is scarce.

Gastric cancer is the third leading cause of cancer deaths worldwide and the most common in eastern Asia. Surgery for gastric cancer is usually accompanied by extended lymph node dissection, known as a D2 lymphadenectomy.[6] The Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) did a preliminary multicentre phase 2 trial (OGSG0202)[7] to examine the clinical outcomes when postoperative antimicrobial prophylaxis is not given to patients with gastric cancer. 56 patients who were scheduled to have a distal gastrectomy were registered in this study. Cefazolin was given 30 min before the skin incision and every 3 h during the operation without postoperative antimicrobial prophylaxis. Surgical-site infections were recorded in three patients (5·4%), which was similar to the prevalence in historical controls who had received postoperative antimicrobial prophylaxis (6·7%).[7] After the

Published Online January 31, 2012 DOI:10.1016/S1473-3099(11)70370-X

See Online/Comment DOI:10.1016/S1473-3099(12)70019-1

*These authors contributed equally to this work

Department of Surgery, Sakai Municipal Hospital, Osaka, Japan (H Imamura MD, H Furukawa MD); **Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan** (Y Kurokawa MD); **Department of Surgery, Osaka National Hospital, Osaka, Japan** (T Tsujinaka MD); **Department of Surgery, Kansai Medical College, Osaka, Japan** (K Inoue MD); **Department of Surgery, NTT West Hospital, Osaka, Japan** (Y Kimura MD); **Department of Surgery, Minoh City Hospital, Osaka, Japan** (S Iijima MD); **Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan** (T Shimokawa PhD)

Correspondence to: Dr Yukinori Kurokawa, Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, 2-2-E2, Yamadaoka, Suita, Osaka, Japan **ykurokawa@gesurg.med.osaka-u.ac.jp**

For **worldwide cancer statistics** see http://globocan.iarc.fr/

phase 2 trial, we designed this multicentre, randomised, phase 3 trial (OGSG0501) to assess non-inferiority of the omission of postoperative antimicrobial prophylaxis in patients with gastric cancer.

Methods

Patients

We enrolled patients who had histologically proven gastric adenocarcinoma that was deemed curable with a distal gastrectomy. Patients were also required to have an American Society of Anesthesiologists (ASA) score of 1 or 2. Patients were excluded from the study if they had an active or uncontrolled infection, received neoadjuvant chemotherapy, or had been given steroids. Seven institutions of the OGSG in Japan participated in the trial. The study protocol was approved by the OGSG Steering Committee and the institutional review boards of all of the participating hospitals. All patients provided written informed consent before randomisation. This study was registered with UMIN-CTR,UMIN000000631.

For the **UMIN-CTR database** see http://www.umin.ac.jp/ctr/

Panel 1: **Definitions of surgical-site infections**[1]

Superficial incisional

Infection occurs within 30 days after the operation and involves only skin or subcutaneous tissue of the incision and at least one of the following:

- purulent drainage, with or without laboratory confirmation, from the superficial incision;
- organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision;
- at least one of the following signs or symptoms of infection: pain or tenderness, localised swelling, redness or heat, and superficial incision is deliberately opened by surgeon, unless incision is culture-negative.

Deep incisional

Infection occurs within 30 days after the operation if no implant is left in place or within 1 year if implant is in place and the infection seems to be related to the operation. The infection involves deep soft tissues (eg, fascial and muscle layers) of the incision and at least one of the following:

- purulent drainage from the deep incision but not from the organ or space component of the surgical site;
- a deep incision spontaneously dehisces or is deliberately opened by a surgeon when the patient has at least one of the following signs or symptoms: fever (>38°C), localised pain, or tenderness, unless site is culture-negative;
- an abscess or other evidence of infection involving the deep incision is found on direct examination, during reoperation, or by histopathological or radiological examination.

Organ or space

Infection occurs within 30 days after the operation if no implant is left in place or within 1 year if implant is in place and the infection seems to be related to the operation. The infection involves any part of the anatomy (eg, organs or spaces), other than the incision, which was opened or manipulated during an operation and at least one of the following:

- purulent drainage from a drain that is placed through a stab wound into the organ or space;
- organisms isolated from an aseptically obtained culture of fluid or tissue in the organ or space;
- an abscess or other evidence of infection involving the organ or space that is found on direct examination, during reoperation, or by histopathological or radiological examination.

Randomisation and masking

After confirming the eligibility of patients during surgery, surgeons contacted the OGSG data centre by telephone to receive a randomly generated assignment (1:1) placing the patients in one of the treatment groups. We used Pocock and Simon's minimisation method to stratify treatment groups according to institution and ASA scores, and Mersenne twister for random number generation.[8] The surgeon gave the assigned treatment. Interventions were not masked. The OGSG data centre was responsible for assigning the intervention, data management, central monitoring, and statistical analyses.

Procedures

For both groups, the surgeon did distal gastrectomies and lymphadenectomies according to Japanese Gastric Cancer Treatment Guidelines.[9] In short, D1 lymphadenectomy plus suprapancreatic node dissection (D1+β dissection) was done for patients with cT1 tumours, whereas D2 lymphadenectomy was done for patients with cT2–4 tumours. The reconstruction method and the surgical approach (open or laparoscopic) were not prespecified.

1 g of cefazolin was given 30 min after anaesthesia, and an additional dose was given every 3 h during surgery. For the extended antimicrobial prophylaxis group, 1 g of cefazolin was given on postoperative day 0 (at night) and every 12 h until postoperative day 2 (2 g per day for 2 postoperative days). Care before and after surgery and wound management were done according to respective institutional standards.

Operative methods and pathology results were recorded according to the 13th edition of the Japanese Classification of Gastric Carcinoma.[10] The prognostic nutritional index was calculated as: $0{\cdot}005\times$lymphocyte count (cells per μL) $+10\times$serum albumin (g/dL).[11] Infection control personnel monitored and detected surgical-site infections during the patient's hospital stay. Principal surgeons were required to check for the presence or absence of surgical-site infections at outpatient clinics until 30 days after surgery. The Centers for Disease Control and Prevention's National Nosocomial Infection Surveillance system was used to diagnose surgical-site infections (panel 1),[1] which were classified as superficial incisional, deep incisional, and organ or space.

Statistical analysis

The primary endpoint was the incidence of surgical-site infections. Secondary endpoints were the incidence of infection at remote sites, the incidence of fever higher than 38°C, body temperature on postoperative day 3, duration of hospital stay after surgery, and severe adverse reactions to antimicrobial prophylaxis.

We intended to recruit 342 patients with a power of 80% for the Dunnet–Gent test at a one-sided α of 0·05 to show non-inferiority of incidence of surgical-site infections. This allowed us to detect a non-inferiority margin of 5% for incidence of surgical-site infections in the intraoperative antimicrobial prophylaxis group with an estimation of a 6·7% incidence of these infections in the extended treatment group. The projected accrual period was 3 years, and no interim analysis was planned.

For secondary endpoints, we compared binary variables with Fisher's exact test, and continuous variables with the Mann-Whitney *U* test. Logistic regression analysis was done to adjust for potential confounding factors, including age, sex, lymphadenectomy, reconstruction method, postoperative cancer stage, body-mass index, prognostic nutritional index, and transfusions. Nine subgroups were also analysed with logistic regression to assess statistical interactions between the treatment and various subgroups. Because of the exploratory nature of subgroup comparisons, test results are reported without multiplicity adjustment of type I error.

Because the study was designed to use a one-sided test, we present one-sided p values for the primary analysis results of the non-inferiority test of surgical-site infections. Two-sided p values were calculated for all other tests. All p values less than 0·05 were judged to be statistically significant. Analysis was by intention-to-treat. Statistical analyses were done with SPSS version 17.0 and R version 2.12.2.

Role of the funding source

This study was funded by OGSG, which is a non-profit organisation established to develop cancer treatment. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

Between June 2, 2005, and Dec 6, 2007, 355 patients from seven hospitals were randomly assigned: 176 to receive intraoperative antimicrobial prophylaxis, and 179 to the extended antimicrobial prophylaxis group (figure 1). Two patients underwent a total gastrectomy because they had a positive resection margin, and one had palliative bypass surgery with gastrointestinal anastomosis. All patients received all planned antimicrobial doses and were monitored during their hospital stay and until 30 days after surgery. No severe adverse reactions to antimicrobial prophylaxis occurred in either group.

The patients' characteristics in the two groups were well balanced (table 1). Median body-mass index and median prognostic nutritional index were much the same between the two groups. About 60% of patients in both groups had early (T1) gastric cancer. A D2 or more extended lymphadenectomy was done in 123 patients assigned to the intraoperative antimicrobial prophylaxis group (70%) and in 120 patients assigned to the extended antimicrobial prophylaxis group (67%). The between-group differences in median operation time was 9 min and in median blood loss was 10 mL. 14 patients had laparoscopy-assisted distal gastrectomy.

24 patients had surgical-site infections (table 2), all of whom had undergone distal gastrectomy without protocol violation. The incidence of surgical-site infections was 5% (95% CI 2–9%) in the intraoperative antimicrobial prophylaxis group compared with 9% (5–14%) in the extended antimicrobial prophylaxis group. Intraoperative administration was non-inferior to postoperative treatment (one-sided p<0·0001). On the basis of a multiple logistic regression analysis, the odds ratios (ORs) for surgical-site infections with intraoperative antimicrobial prophylaxis was 0·49 (95% CI 0·20–1·16) before and 0·55 (0·21–1·45) after adjusting for eight variables (age, sex, lymphadenectomy, reconstruction method, postoperative cancer stage, body-mass index, prognostic nutritional index, and transfusions).

Most surgical-site infections involved organ or space, and no deep incisional infections arose (table 2).

We assessed statistical interactions between the treatment effects and patient characteristics, including body-mass index, prognostic nutritional index, and operation time (figure 2). No subgroups showed a decrease in the incidence of surgical-site infections with extended antimicrobial prophylaxis. The OR for surgical site infections with intraoperative antimicrobial prophylaxis was 0·31 (95% CI 0·099–0·998; p=0·050) for patients who were not overweight (body-mass index <25)



Figure 1: **Trial profile**
AMP=antimicrobial prophylaxis.

	Intraoperative AMP (n=176)	Extended AMP (n=179)
Age (years)	66 (36–84)	65 (35–84)
Sex		
Male	115	125
Female	61	54
Lymphadenectomy		
D1*	53	59
D2–3	123	120
Reconstruction method		
Billroth-I	83	103
Billroth-II	3	1
Roux-Y	90	75
pT stage		
T1	104	111
T2	46	42
T3–4	26	26
pN stage		
N0	114	122
N1	38	36
N2–3	24	21
Body-mass index	22·3 (16·3–33·0)	22·5 (12·4–32·9)
Prognostic nutrition index†	51·1 (25·1–68·9)	51·7 (26·6–66·0)
Approach		
Open	169	172
Laparoscopic	7	7
Anastomotic method		
Hand-sewn	21	34
Autosuture	119	119
Mixed	36	26
Drainage tube		
Yes	157	153
No	19	26
Operation time (min)	209 (58–428)	200 (64–415)
Blood loss (mL)	200 (1–880)	210 (1–1700)
Transfusion		
Yes	0	4
No	176	175

Data are number or median (range). AMP=antimicrobial prophylaxis. pT=primary tumour. pN=lymph node status. *One patient in the extended AMP group who underwent palliative bypass surgery was included in D1. †Data from 28 patients in the intraoperative AMP group and 23 patients in the extended AMP group are missing.

Table 1: **Characteristics of patients**

	Intraoperative AMP (n=176)	Extended AMP (n=179)	Relative risk (95% CI)	p value*
Surgical-site infections	8 (5%)	16 (9%)	0·51 (0·22–1·16)	0·138
Superficial incisional	1 (<1%)	5 (3%)	..	0·215
Deep incisional	0	0	..	..
Organ or space	7 (4%)	11 (6%)	..	0·469
With anastomotic leakage	1	4	..	..
Without anastomotic leakage	6	7	..	..

AMP=antimicrobial prophylaxis. *Two-sided p value for superiority test.

Table 2: **Incidence of surgical-site infections**

and 1·09 (0·25–4·72; 0·91) for patients who were overweight (body-mass index ≥25).

All secondary endpoints were compared between the intraoperative antimicrobial prophylaxis group and extended administration group (table 3). The incidence of remote site infections was 5% (95% CI 2–10) with intraoperative antimicrobial prophylaxis and 3% (1–7) with extended treatment. For remote site infections, two patients had pneumonia or bronchitis and one patient had a urinary tract infection in each group. The incidence of fever higher than 38°C was 34% (27·1–41·6) and 29% (22·5–36·3) in the intraoperative and extended groups, respectively. Median body temperature on postoperative day 3 was about 37°C in both groups and median duration of hospital stay was 12 days with both treatments.

Discussion

Omitting postoperative antimicrobial prophylaxis does not increase the incidence of surgical-site infections in patients with gastric cancer. Extended antimicrobial prophylaxis is associated with greater costs than intraoperative treatment alone because of the use of unnecessary drugs and might increase the risk of adverse drug reactions. Additionally, shortening of the antimicrobial prophylaxis period could help prevent the emergence of resistant strains.[12,13] For these reasons, we do not recommend antimicrobial prophylaxis after gastric cancer surgery.

In a US study, about 60% of patients who had had major surgery were still receiving antimicrobial prophylaxis at 24 h after surgery.[3] Results of a survey of 14 high-volume hospitals in South Korea and Japan showed that at 11 institutions antimicrobial prophylaxis was routinely given for longer than 24 h.[14] Although the national surgical infection prevention guidelines in the USA recommend that this treatment should be discontinued within 24 h of surgery,[15] this approach has not yet been adopted worldwide, because the recommendation is not based on clear evidence. Previously, the standard surgical treatment for gastric cancer was extended D2 lymphadenectomy in eastern Asia,[6,16] but was limited to D0 or D1 lymphadenectomy in the USA and Europe.[17,18] However, in 2010, the European Society for Medical Oncology guidelines for gastric cancer[19] were revised and they now recommend an extended D2 lymphadenectomy as the standard procedure, as in Japanese guidelines. Furthermore, in the latest version (2.2011) of the National Comprehensive Cancer Network Guidelines for gastric cancer, an extended D2 lymphadenectomy was recommended in the USA.[20] Therefore, the question of the appropriate length of antimicrobial prophylaxis after an extended D2 gastrectomy is relevant worldwide.

Mohri and colleagues[21] reported that the incidence of surgical-site infection in gastric cancer surgery was much the same (9·5% *vs* 8·6%) for single-dose and multiple-dose antimicrobial prophylaxis, although their study did not fix the type of surgery and the antibiotics to a single

drug (panel 2). Other retrospective studies have reported incidences of surgical-site infections of 8–12% after a gastrectomy.[23,24] In our phase 3 study, the overall incidence of these infections was 5% in the intraoperative antimicrobial prophylaxis group, which was much the same as the incidence in our previous phase 2 trial (5·4%). The Japanese health system is a suitable setting in which to assess the frequency of surgical-site infections because Japanese institutions allow a long hospital stay after surgery. The median length hospital stay after surgery was 12 days in each group, which enabled infection control personnel to accurately assess the incidence of surgical-site infections for almost half of the follow-up period. Our study required the principal surgeons to check for the presence or absence of surgical-site infections at outpatient clinics until 30 days after surgery. Systematic measurement instruments, which are independent of principal investigators, often result in an underestimation of the incidence of surgical-site infections.[25] Therefore, our results are likely to be an accurate assessment of the frequency of surgical-site infections after a distal gastrectomy.

Several factors such as obesity, malnutrition, transfusions, and operation time increase the incidence of surgical-site infections.[23,26–29] In this study, body-mass index, prognostic nutritional index, and operation time were much the same between the two groups. However, the number of patients who required a transfusion differed between the two groups (none in the intraoperative group and four in the extended group). Of the four patients who received a transfusion, one had an organ or space surgical-site infection after the gastrectomy, which might have led to the unexpected result that the incidence of surgical-site infections was higher in the extended antimicrobial prophylaxis group than in the intraoperative administration group. However, after adjusting for all the potential confounding factors including transfusions by a multivariate analysis, the OR for surgical-site infection with intraoperative antimicrobial prophylaxis was essentially unchanged (0·49 before adjustment *vs* 0·55 after adjustment). An Italian small-scale randomised study[22] that included patients with gastric cancer and colorectal cancer reported that the incidence of surgical-site infections was 16·1% in the intraoperative antimicrobial prophylaxis group and 44·0% in the extended administration group (panel 2). These results and ours suggest that elimination of postoperative antimicrobial prophylaxis might in fact reduce the risk of such infections, although our study was not planned to assess superiority.

The incidence of surgical-site infections in patients who were not overweight (body-mass index <25) was significantly higher in the extended group than in the intraoperative group (p=0·05), whereas the incidence of these infections in patients who were overweight (body-mass index ≥25) was almost same between the two groups (p=0·91). Why postoperative antimicrobial prophylaxis significantly increased the incidence of surgical-site infections in patients who were not overweight is unclear. In the additional analysis in this



Figure 2: **Forest plot of subgroup analyses**
p values for interactions and odds ratios for surgical-site infections with intraoperative antimicrobial prophylaxis (AMP). *Data for prognostic nutrition index from 51 patients are missing.

	Intraoperative AMP (n=176)	Extended AMP (n=179)	Relative risk (95% CI)	p value
Remote site infections	..	..	1·53 (0·56–4·20)	0·441
Yes	9	6	..	
No	167	173	..	
Fever higher than 38°C	60	52	1·17 (0·86–1·60)	0·361
Body temperature on POD 3 (°C)	37·0 (35·7–40·0)	36·9 (35·3–39·1)	..	0·145
Duration of hospital stay after surgery (days)	12 (7–114)	12 (7–87)	..	0·742

Data are number or median (range) unless otherwise specified. AMP=antimicrobial prophylaxis. POD=postoperative day.

Table 3: **Secondary endpoints**

Panel 2: Research in context

Systematic review

We searched PubMed with the terms "gastric cancer", "surgery", and "antibiotics". Two randomised controlled studies[21,22] including patients with gastric cancer have been reported. A small-scale study in Italy[22] included both patients with gastric cancer and those with colorectal cancer and compared 1-day antimicrobial prophylaxis with clindamycin plus gentamicin to 7-day antimicrobial prophylaxis with ampicillin. A Japanese study compared intraoperative antimicrobial prophylaxis to intraoperative plus postoperative (until 3 postoperative days) treatment with cefazolin or ampicillin-sulbactam.[21] Neither study fixed the type of surgery or the antibiotics to a single agent.

Interpretation

Most of the previous studies used as the basis for the US Centers for Disease Control and Prevention guidelines did not include patients with gastric cancer. Because of absence of strong evidence to show that intraoperative administration of antimicrobial prophylaxis is sufficient to prevent surgical-site infections after D2 gastrectomy, antimicrobial prophylaxis is commonly prescribed for more than 24 h to prevent postoperative complications. Our multicentre study group did a phase 2 study to assess the feasibility of intraoperative antimicrobial prophylaxis alone and to confirm the prevalence of surgical-site infections after distal gastrectomy.[7] This is the first phase 3 study to assess the effectiveness of a fixed regimen for postoperative antimicrobial prophylaxis after distal gastrectomy. Our results show that postoperative antimicrobial prophylaxis is not recommended for patients with gastric cancer even after extended lymphadenectomy.

subgroup, patients who were underweight (body-mass index <18·5) and those of normal weight (body-mass index ≥18·5 and <25) had much the same OR for surgical-site infections (underweight 0·36, 95% CI 0·03–4·50; normal weight 0·29, 0·078–1·08). This result could be a false positive resulting from multiple testing. However, this does not affect the most important findings, which are that extended antimicrobial prophylaxis did not decrease the incidence, even in high-risk subgroups, such as patients with a high body-mass index, low prognostic nutritional index, or long operation time.

Our study included only patients with gastric cancer undergoing a distal gastrectomy. A total gastrectomy is usually associated with greater blood loss and a longer operation time than a distal gastrectomy. Because extended antimicrobial prophylaxis was not beneficial in this study, even in subgroups with a long operation time or much blood loss, we believe that our conclusion can be applied to patients with gastric cancer who are undergoing a total gastrectomy and therefore have a similar microflora in the operative field. However, our findings might not apply to patients who require surgery for other organs such as the colon or hepatobiliary tract because of differences in the microflora in the operative field and the baseline incidence of surgical-site infections.[24,30] Further studies are needed to assess postoperative antimicrobial prophylaxis with surgeries that typically have an increased incidence of surgical-site infections.

In three patients who had protocol violations, no surgical-site infections were recorded. Therefore, per-protocol analysis excluding these three patients gave much the same results as the intention-to-treat analysis. One of the limitations of our study was the absence of blinding. We did not use a placebo in this study, and surgeons and care providers were not masked to treatment allocation. The protocol did not specify that patients should be told about their allocation, so that whether they were masked to their treatment group is uncertain. However, during hospital stay, the assessment of surgical-site infections was done by infection control personnel who were not involved in this study. Therefore, we feel the possibility of a bias in assessment of endpoints is negligible.

Contributors

HI and HF conceived and designed the trial. Data collection and statistical analyses were done by TS. YKu and TT drafted the paper. KI, YKi, and SI revised the paper. All authors approved the final version.

Conflicts of interest

We declare that we have no conflicts of interest.

Acknowledgments

We thank Akiko Hotta for data management, and Takashi Morimoto and Mitsutoshi Tatsumi for participating in this trial. The study was funded by OGSG.

References

1 Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. *Infect Control Hosp Epidemiol* 1999; **20:** 250–78.

2 Hranjec T, Swenson BR, Sawyer RG. Surgical site infection prevention: how we do it. *Surg Infect* 2010; **11:** 289–94.

3 Bratzler DW, Houck PM, Richards C, et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. *Arch Surg* 2005; **140:** 174–82.

4 Sumiyama Y, Takesue Y. Current status of prophylactic antibiotic therapy for prevention of postoperative infections after gastrointestinal surgery: a questionnaire covering 3,823 surgeons. *Jpn J Chemotherapy* 2004; **52:** 474–85 (in Japanese).

5 Utsumi M, Shimizu J, Miyamoto A, et al. Age as an independent risk factor for surgical site infections in a large gastrointestinal surgery cohort in Japan. *J Hosp Infect* 2010; **75:** 183–87.

6 Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. *N Engl J Med* 2008; **359:** 453–62.

7 Imamura H, Furukawa H, Iijima S, et al. Multicenter phase II study of antimicrobial prophylaxis in low-risk patients undergoing distal gastrectomy for gastric cancer. *Gastric Cancer* 2006; **9:** 32–35.

8 Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. *Biometrics* 1975; **31:** 103–15.

9 Japanese Gastric Cancer Association. Gastric cancer treatment guidelines. Tokyo: Kanehara, 2004 (in Japanese).

10 Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma—2nd English edition. *Gastric Cancer* 1998; **1:** 10–24.

11 Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. *Nippon Geka Gakkai Zasshi* 1984; **85:** 1001–05 (in Japanese).

12 Nichols RL. Current strategies for prevention of surgical site infections. *Curr Infect Dis Rep* 2004; **6:** 426–34.

13 Itani KM, Wilson SE, Awad SS, et al. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. *N Engl J Med* 2006; **355:** 2640–51.

14 Ahn HS, Yook JH, Park CH, et al. General perioperative management of gastric cancer patients at high-volume centers. *Gastric Cancer* 2011; **14:** 178–82.

15 Bratzler DW, Houck PM, for the Surgical Infection Prevention Guidelines Writers Workgroup. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. *Clin Infect Dis* 2004; **38:** 1706–15.

16 Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. *Lancet Oncol* 2006; **7:** 309–15.

17 Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. *N Engl J Med* 1999; **340:** 908–14.

18 Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001; **345:** 725–30.

19 Okines A, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2010; **21** (suppl 5)**:** v50–54.

20 National Comprehensive Cancer Network. Guidelines for gastric cancer Ver 2.2011. http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf (accessed Jan 21, 2012).

21 Mohri Y, Tonouchi H, Kobayashi M, et al. Randomized clinical trial of single- versus multiple-dose antimicrobial prophylaxis in gastric cancer surgery. *Br J Surg* 2007; **94:** 683–88.

22 Braga M, Baccari P, Di Palo S, et al. Effectiveness of perioperative short-term antibiotic prophylaxis in reducing surgical risk induced by malnutrition and anergy. *Acta Chir Scand* 1990; **156:** 751–57.

23 Imai E, Ueda M, Kanao K, et al. Surgical site infection risk factors identified by multivariate analysis for patient undergoing laparoscopic, open colon, and gastric surgery. *Am J Infect Control* 2008; **36:** 727–31.

24 Suehiro T, Hirashita T, Araki S, et al. Prolonged antibiotic prophylaxis longer than 24 hours does not decrease surgical site infection after elective gastric and colorectal surgery. *Hepatogastroenterology* 2008; **55:** 1636–39.

25 Smith RL, Bohl JK, McElearney ST, et al. Wound infection after elective colorectal resection. *Ann Surg* 2004; **239:** 599–605.

26 Tsujinaka T, Sasako M, Yamamoto S, et al. Influence of overweight on surgical complications for gastric cancer: results from a randomized control trial comparing D2 and extended para-aortic D3 lymphadenectomy (JCOG9501). *Ann Surg Oncol* 2007; **14:** 355–61.

27 Ozalp N, Zülfikaroğlu B, Göçmen E, et al. Risk factors for surgical site infection after gastrectomy with D2 lymphadenectomy. *Surg Today* 2009; **39:** 1013–15.

28 Malone DL, Genuit T, Tracy JK, et al. Surgical site infections: reanalysis of risk factors. *J Surg Res* 2002; **103:** 89–95.

29 Bernard AC, Davenport DL, Chang PK, et al. Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients. *J Am Coll Surg* 2009; **208:** 931–37.

30 Gaynes RP, Culver DH, Horan TC, et al. Surgical site infection (SSI) rates in the United States, 1992–1998: the National Nosocomial Infections Surveillance System basic SSI risk index. *Clin Infect Dis* 2001; **33** (suppl 2)**:** S69–77.